Faron Pharmaceuticals is a clinical-stage biopharmaceutical company that is dedicated to addressing unmet medical needs in cancer and improving patient lives. With a focus on developing innovative immunotherapies, Faron is utilizing a clever approach to fight cancer. Their flagship product, bexmarilimab, is a first-in-class, humanized antibody that targets the Clever-1 receptor found on myeloid cells and macrophages.

Clever-1 is an immunosuppressive receptor that promotes tumor growth and metastases when expressed on macrophages. By binding to this receptor, bexmarilimab primes the tumor microenvironment for optimal antitumor immune responses, offering a promising solution for both hematological malignancies and solid tumors. At Faron Pharmaceuticals, they are continuously making significant strides in their bexmarilimab program, with exciting early data in hematologic malignancies and solid tumors.

These achievements are a testament to the dedication of their team and the invaluable support of their shareholders. Faron Pharmaceuticals envisions a bright future in the fight against cancer and remains committed to improving patient outcomes